{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:55:53Z","timestamp":1780462553939,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s12325-020-01395-x","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T17:02:38Z","timestamp":1591808558000},"page":"3404-3416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase\u00a03 Study\u2014Asian Subgroup Analysis"],"prefix":"10.1007","volume":"37","author":[{"given":"Shang-Yi","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Shyong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Siu-Ming","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seasea","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve W.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Glennane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ki","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,10]]},"reference":[{"key":"1395_CR1","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","volume":"5","author":"C Fitzmaurice","year":"2019","unstructured":"Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Abate D, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2019;5:1749\u201368.","journal-title":"JAMA Oncol"},{"key":"1395_CR2","unstructured":"The Global Cancer Observatory. Malaysia fact sheet. http:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/458-malaysia-fact-sheets.pdf. Accessed Dec 11, 2019."},{"key":"1395_CR3","unstructured":"The Global Cancer Observatory. Japan fact sheet. http:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/392-japan-fact-sheets.pdf. Accessed Dec 11, 2019."},{"key":"1395_CR4","unstructured":"The Global Cancer Observatory. Republic of Korea fact sheet. http:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/410-korea-republic-of-fact-sheets.pdf. Accessed Dec 11, 2019."},{"key":"1395_CR5","unstructured":"The Global Cancer Observatory. Singapore fact sheet. http:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/702-singapore-fact-sheets.pdf. Accessed Dec 11, 2019."},{"key":"1395_CR6","unstructured":"The Global Cancer Observatory. Asia Fact Sheet. http:\/\/gco.iarc.fr\/today\/data\/factsheets\/populations\/935-asia-fact-sheets.pdf. Accessed Dec 11, 2019."},{"key":"1395_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13045-019-0807-5","volume":"12","author":"J Liu","year":"2019","unstructured":"Liu J, Liu W, Mi L, et al. Incidence and mortality of multiple myeloma in China, 2006\u20132016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019;12:136.","journal-title":"J Hematol Oncol"},{"key":"1395_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.canep.2018.06.003","volume":"55","author":"CH Tang","year":"2018","unstructured":"Tang CH, Liu HY, Hou HA, et al. Epidemiology of multiple myeloma in Taiwan, a population based study. Cancer Epidemiol. 2018;55:136\u201341.","journal-title":"Cancer Epidemiol"},{"key":"1395_CR9","first-page":"285","volume":"15","author":"EK O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell EK, Raje NS. Myeloma bone disease: pathogenesis and treatment. Clin Adv Hematol Oncol. 2017;15:285\u201395.","journal-title":"Clin Adv Hematol Oncol"},{"key":"1395_CR10","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1056\/NEJMra030831","volume":"350","author":"GD Roodman","year":"2004","unstructured":"Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655\u201364.","journal-title":"N Engl J Med"},{"key":"1395_CR11","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","volume":"48","author":"A Lipton","year":"2012","unstructured":"Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase\u00a03 trials. Eur J Cancer. 2012;48:3082\u201392.","journal-title":"Eur J Cancer"},{"key":"1395_CR12","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","volume":"102","author":"E Terpos","year":"2003","unstructured":"Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood. 2003;102:1064\u20139.","journal-title":"Blood"},{"key":"1395_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41408-017-0037-4","volume":"8","author":"E Terpos","year":"2018","unstructured":"Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, Dimopoulos MA. Pathogenesis of bone disease in multiple myeloma: from bench to bedside. Blood Cancer J. 2018;8:7.","journal-title":"Blood Cancer J"},{"key":"1395_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/ajh.23731","volume":"89","author":"K Kim","year":"2014","unstructured":"Kim K, Lee JH, Kim JS, et al. Clinical profiles of multiple myeloma in Asia-an Asian Myeloma Network study. Am J Hematol. 2014;89:751\u20136.","journal-title":"Am J Hematol"},{"key":"1395_CR15","unstructured":"National Cancer Institute. SEER cancer stat facts: myeloma. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed Dec 12, 2019."},{"key":"1395_CR16","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1200\/JCO.2017.76.6402","volume":"36","author":"K Anderson","year":"2018","unstructured":"Anderson K, Ismaila N, Flynn PJ, et al. Role of bone-modifying agents in multiple myeloma: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2018;36:812\u20138.","journal-title":"J Clin Oncol"},{"key":"1395_CR17","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/17474086.2018.1531702","volume":"11","author":"N Kanellias","year":"2018","unstructured":"Kanellias N, Gavriatopoulou M, Terpos E, Dimopoulos MA. Management of multiple myeloma bone disease: impact of treatment on renal function. Expert Rev Hematol. 2018;11:881\u20138.","journal-title":"Expert Rev Hematol"},{"key":"1395_CR18","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/imj.13502","volume":"47","author":"OL Lee","year":"2017","unstructured":"Lee OL, Horvath N, Lee C, et al. Bisphosphonate guidelines for treatment and prevention of myeloma bone disease. Intern Med J. 2017;47:938\u201351.","journal-title":"Intern Med J"},{"key":"1395_CR19","doi-asserted-by":"crossref","unstructured":"Mhaskar R, Kumar A, Miladinovic B, Djulbegovic B. Bisphosphonates in multiple myeloma: an updated network meta-analysis. Cochrane Database Syst Rev. 2017;12:CD003188.","DOI":"10.1002\/14651858.CD003188.pub4"},{"key":"1395_CR20","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","volume":"20","author":"E Terpos","year":"2009","unstructured":"Terpos E, Sezer O, Croucher PI, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol. 2009;20:1303\u201317.","journal-title":"Ann Oncol"},{"key":"1395_CR21","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","volume":"19","author":"N Raje","year":"2018","unstructured":"Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase\u00a03 study. Lancet Oncol. 2018;19:370\u201381.","journal-title":"Lancet Oncol"},{"key":"1395_CR22","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol. 2011;29:1125\u201332.","journal-title":"J Clin Oncol"},{"key":"1395_CR23","unstructured":"Amgen Inc. Xgeva (denosumab) prescribing information. https:\/\/www.pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/xgeva\/xgeva_pi.pdf. Accessed Nov 14, 2019."},{"key":"1395_CR24","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00520-013-2022-1","volume":"22","author":"D Henry","year":"2014","unstructured":"Henry D, Vadhan-Raj S, Hirsh V, et al. Delaying skeletal-related events in a randomized phase\u00a03 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer. 2014;22:679\u201387.","journal-title":"Support Care Cancer"},{"key":"1395_CR25","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol. 2010;28:5132\u20139.","journal-title":"J Clin Oncol"},{"key":"1395_CR26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813\u201322.","journal-title":"Lancet"},{"key":"1395_CR27","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdu519","volume":"26","author":"MR Smith","year":"2015","unstructured":"Smith MR, Coleman RE, Klotz L, et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol. 2015;26:368\u201374.","journal-title":"Ann Oncol"},{"key":"1395_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/s12891-018-2338-6","volume":"19","author":"C Zhang","year":"2018","unstructured":"Zhang C, Zhang F, Liang G, et al. Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years. BMC Musculoskelet Disord. 2018;19:424.","journal-title":"BMC Musculoskelet Disord"},{"key":"1395_CR29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3349\/ymj.2016.57.4.905","volume":"57","author":"JM Koh","year":"2016","unstructured":"Koh JM, Chung DJ, Chung YS, et al. Assessment of denosumab in Korean postmenopausal women with osteoporosis: randomized, double-blind, placebo-controlled trial with open-label extension. Yonsei Med J. 2016;57:905\u201314.","journal-title":"Yonsei Med J"},{"key":"1395_CR30","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1210\/jc.2013-4175","volume":"99","author":"T Nakamura","year":"2014","unstructured":"Nakamura T, Matsumoto T, Sugimoto T, et al. Clinical Trials Express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014;99:2599\u2013607.","journal-title":"J Clin Endocrinol Metab"},{"key":"1395_CR31","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/annrheumdis-2015-208052","volume":"75","author":"T Takeuchi","year":"2016","unstructured":"Takeuchi T, Tanaka Y, Ishiguro N, et al. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann Rheum Dis. 2016;75:983\u201390.","journal-title":"Ann Rheum Dis"},{"key":"1395_CR32","unstructured":"Zometa\u00ae (zoledronic acid). Full prescribing information, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2016."},{"key":"1395_CR33","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s10147-016-1019-4","volume":"21","author":"M Yamasaki","year":"2016","unstructured":"Yamasaki M, Yuasa T, Uehara S, et al. Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab. Int J Clin Oncol. 2016;21:1191\u20135.","journal-title":"Int J Clin Oncol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01395-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-020-01395-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-020-01395-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T08:20:05Z","timestamp":1625127605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-020-01395-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,10]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["1395"],"URL":"https:\/\/doi.org\/10.1007\/s12325-020-01395-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,10]]},"assertion":[{"value":"29 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}